Detoxifit

INSTRUCTIONS FOR MEDICAL USE OF THE MEDICINAL PRODUCT DETOKSIFIT

Composition:

Active ingredients: 1 package (100 g) contains a mixture of medicinal plant raw materials: herb of Bidens (Bidentis herba) 6 g, rhizome with roots of Acorus calamus (Calamis rhizoma) 5 g, herb of Vinca minor (Vincae minoris herba) 5 g, herb of Melilotus (Meliloti herba) 5 g, herb of Achillea (Millefolii herba) 5 g, seeds of Aesculus hippocastanum (Hippocastani semen) 5 g, corn silk of Zea mays (Zea mays styli cum stigmatis) 5 g, roots of Taraxacum officinale (Taraxaci officinalis radix) 5 g, roots of Arctium lappa (Arctii radix) 5 g, leaves of Uva ursi (Uvae ursi folium) 5 g, flowers of Matricaria (Matricariae flos) 5 g, roots of Glycyrrhiza (Liquiritiae radix) 5 g, buds of Pinus sylvestris (Pinus sylvestris gemmae) 5 g, herb of Equisetum (Equiseti herba) 5 g, hops of Humulus lupulus (Lupuli flos) 5 g, roots of Valeriana (Valerianae radix) 4 g, herb of Hypericum (Hyperici herba) 4 g, herb of Leonurus cardiaca (Leonuri cardiaca herba) 4 g, leaves of Mentha piperita (Menthae piperitae folium) 4 g, herb of Chelidonium (Chelidonii herba) 4 g, fruits of Rosa (Rosae pseudo-fructus) 4 g.

Pharmaceutical form. Herbal mixture.

Main physico-chemical properties: a mixture of irregularly shaped fragments of greyish-green color with white, yellow, orange and brownish inclusions. Odor is weak, pleasant.

Pharmacotherapeutic group.

Agents affecting the digestive system and metabolic processes. ATC code A16AX.

Pharmacological properties.

Pharmacodynamics. The medicinal product exhibits hypoazotemic, mild saluretic and diuretic effects; promotes the removal of salt deposits from joints and spine. Reduces cholesterol and triglyceride levels in blood plasma in hyperlipidemia, slows the progression of atherosclerosis, and promotes regression of existing atherosclerotic plaques. Positively affects hepatic urea formation and renal depurative function. Improves the liver's antitoxic function. Has choleretic, spasmolytic, anti-inflammatory, capillary-protective, and anti-edematous effects.

Clinical characteristics.

Indications. As part of complex therapy for atherosclerosis; arterial hypertension; gout during remission period; urolithiasis; edema; liver and biliary tract diseases (chronic hepatitis, chronic cholecystitis, cholangitis); stages I–II of varicose vein expansion; asthenic syndrome.

Contraindications. Hypersensitivity to any component of the drug. Exacerbation stage of gastric and duodenal ulcer, jaundice, cholelithiasis, acute cholecystitis, acute hepatitis, liver cirrhosis, glomerulonephritis, acute and chronic renal failure, thrombophlebitis, arterial hypotension, bradycardia, hypokalemia.

Special precautions. When using the drug for a prolonged period (more than two months), electrolyte balance parameters should be monitored (plasma levels of potassium, magnesium, sodium, and calcium).

The drug should be used with caution in patients with epilepsy, bronchial asthma, and those predisposed to bronchospasm and tetany. During treatment, exposure to intense UV radiation should be avoided.

Interaction with other medicinal products and other types of interactions. Concurrent use with indirect anticoagulants, antibiotics, sulfonamides, contraceptives, antihypertensive drugs—calcium channel blockers, female sex hormones, hypocholesterolemic agents (statins), and cardiac glycosides is not recommended.

Prolonged concurrent use with adrenocorticosteroids, antiarrhythmic agents (quinidine), laxatives, and thiazide or loop diuretics may lead to disturbances in water-electrolyte balance.

Instructions for use.

Use during pregnancy or breastfeeding. Due to the lack of sufficient experience with the use of the medicinal product during pregnancy, it should be used during pregnancy only upon a physician's recommendation, when the expected benefit to the mother outweighs the potential risk to fetal development. If it is necessary to use the drug, breastfeeding should be discontinued.

Ability to influence reaction rate while driving or operating machinery. Does not affect.

Method of Administration and Dosage.

Steep 2 tablespoons of the herbal mixture in 500 mL of boiling water, cover and let stand for 1 hour, then strain.

For adults: take 150 mL warm, 20–30 minutes before meals, 3 times daily.

For children aged 12 years and older: take 75 mL warm, 20–30 minutes before meals, 3 times daily.

Duration of use should be determined by a physician. Typically, treatment course lasts 1.5–2.5 months. If necessary, the course may be repeated as directed by a physician.

Children. The preparation is contraindicated for children under 12 years of age.

Overdose. May result in an intensification of adverse reactions.

Adverse Reactions

The medicinal product is generally well tolerated by patients. However, due to its multi-component composition, allergic reactions may occur, particularly in cases of individual hypersensitivity to any of the components or when the recommended dosage regimen is not followed. Such reactions may include itching, rash, hyperemia, urticaria, dermatitis, skin swelling, and photosensitivity. Gastrointestinal disturbances (nausea, vomiting, diarrhea) and drowsiness are also possible.

Scientific publications report that the use of bearberry leaves may cause lumbar pain, changes in urine color, and pain at the end of urination. Although the DETOKSIFIT herbal blend contains only a small amount of bearberry leaves, such symptoms cannot be completely excluded.

If any adverse reactions occur, medical advice should be sought immediately.

Shelf Life. 2 years. Do not use after the expiry date stated on the packaging.

Storage Conditions. In the original packaging at a temperature not exceeding 25 °C, in a place inaccessible to children.

Packaging. 100 g per packet, placed in a carton.

Availability. Over-the-counter (without prescription).

Manufacturer. LLC "Scientific and Production Pharmaceutical Company "EYM".

Manufacturer's Address. 20 Lityera "A-5", Kharkivskykh Diviziy Street, Kharkiv, Kharkiv Oblast, 61091, Ukraine.

INSTRUCTION

for medical use of the medicinal product

DETOKSIFIT

Composition:

Active substances: 1 filter bag (1.5 g) contains a mixture of herbal raw materials:
Bidens herb (Bidentis herba) 90 mg,
calamus rhizome (Calami radix) 75 mg,
lesser periwinkle herb (Vinca minoris herba) 75 mg,
melilot herb (Meliloti herba) 75 mg,
yarrow herb (Millefolii herba) 75 mg,
horse chestnut seed (Hippocastani semen) 75 mg,
corn silk (stigmas with styles) (Zea mays styli cum stigmatibus) 75 mg,
dandelion root (Taraxaci officinalis radix) 75 mg,
burdock root (Arctii radix) 75 mg,
bearberry leaf (Uvae ursi folium) 75 mg,
chamomile flowers (Matricariae flos) 75 mg,
liquorice root (Glycyrrhizae radix) 75 mg,
pine buds (Pinus sylvestris gemmae) 75 mg,
horsetail herb (Equiseti herba) 75 mg,
hops (Lupuli flos) 75 mg,
valerian root (Valerianae radix) 60 mg,
St. John's wort herb (Hyperici herba) 60 mg,
motherwort herb (Leonuri cardiaca herba) 60 mg,
peppermint leaf (Menthae piperitae folium) 60 mg,
celandine herb (Chelidonii herba) 60 mg,
rosehip fruit (Rosae pseudo-fructus) 60 mg.

Pharmaceutical form. Herbal mixture.

Main physico-chemical properties: a mixture of fragments of various shapes, grayish-green in color, with white, yellow, orange and brownish inclusions. Odor is weak, pleasant.

Pharmacotherapeutic group.
Agents affecting the digestive system and metabolic processes. ATC code A16A X.

Pharmacological properties.

Pharmacodynamics. The medicinal product exhibits hypoazotemic, mild saluretic and diuretic effects; promotes the removal of salt deposits from joints and spine. Reduces cholesterol and triglyceride levels in blood plasma in hyperlipidemia, slows the progression of atherosclerosis, and promotes regression of existing atherosclerotic plaques. Exerts a positive effect on hepatic urea synthesis and renal depurative function. Improves the liver's antitoxic function. Has choleretic, spasmolytic, anti-inflammatory, capillary-protective, and anti-edematous actions.

Clinical characteristics.

Indications. As part of complex therapy for atherosclerosis; arterial hypertension; gout during remission period; urolithiasis; edema; liver and biliary tract diseases (chronic hepatitis, chronic cholecystitis, cholangitis); stage I–II varicose vein expansion; asthenic syndrome.

Contraindications. Hypersensitivity to any component of the drug. Exacerbation stage of gastric and duodenal peptic ulcer, jaundice, cholelithiasis, acute cholecystitis, acute hepatitis, liver cirrhosis, glomerulonephritis, acute and chronic renal failure, thrombophlebitis, arterial hypotension, bradycardia, hypokalemia.

Special precautions. When using the drug for a prolonged period (more than two months), parameters of water-electrolyte balance (plasma levels of potassium, magnesium, sodium, and calcium) should be monitored.

The drug should be used with caution in patients with epilepsy, bronchial asthma, and in patients prone to bronchospasm and tetany. During treatment, intense UV radiation should be avoided.

Interaction with other medicinal products and other types of interactions. Concurrent use with indirect anticoagulants, antibiotics, sulfonamides, contraceptives, antihypertensive drugs – calcium channel blockers, female sex hormones, hypocholesterolemic agents (statins), and cardiac glycosides is not recommended.

Prolonged concurrent use with adrenocorticosteroids, antiarrhythmic agents (quinidine), laxatives, and thiazide or loop diuretics may lead to disturbances in water-electrolyte balance.

Special precautions.

Use during pregnancy or breastfeeding. Due to the lack of sufficient experience with the use of the medicinal product during pregnancy, it should be used during pregnancy only on the advice of a physician, when the expected benefit to the mother outweighs the potential risk to fetal development. If it is necessary to use the drug, breastfeeding should be discontinued.

Ability to affect reaction rate when driving or operating machinery. Has no effect.

Dosage and Administration.

Pour 150 ml of boiling water over 2 filter bags, and let steep in a closed container for 15 minutes.

For adults: take 150 ml warm, 20–30 minutes before meals, three times daily.

For children aged 12 years and older: take 75 ml warm, 20–30 minutes before meals, three times daily.

Duration of use should be determined by a physician. Typically, treatment course lasts 1.5–2.5 months. If necessary, the treatment course may be repeated as prescribed by a doctor.

Children. The drug is contraindicated in children under 12 years of age.

Overdose. May result in increased intensity of adverse reactions.

Adverse reactions.

The medicinal product is generally well tolerated by patients. However, due to its multi-component composition, allergic reactions are possible, mostly in cases of individual hypersensitivity to any of the components or in case of violation of the recommended dosage regimen. Such reactions may include itching, rash, hyperemia, urticaria, dermatitis, skin edema, and photosensitivity. Gastrointestinal disturbances (nausea, vomiting, diarrhea) and drowsiness may also occur.

Scientific publications report that the use of bearberry leaves may cause lumbar pain, changes in urine color, and pain at the end of urination. Although the DETOKSIFIT tea blend contains only a small amount of bearberry leaves, such symptoms cannot be completely excluded.

In case of any adverse reactions, consult a physician.

Shelf life. 2 years. Do not use after the expiry date stated on the package.

Storage conditions. In the original packaging at a temperature not exceeding 25 °C, in a place inaccessible to children.

Packaging. 1.5 g per filter bag, 20 bags per pack.

Supply category. Over-the-counter.

Manufacturer. Limited Liability Company "Scientific-Production Pharmaceutical Company "EYM".

Manufacturer's address. 20 lit. "A-5", Kharkivs'kykh Dyviziy St., Kharkiv, Kharkiv region, 61091, Ukraine.